## Amal Kamal Abdel-Aziz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7999045/publications.pdf

Version: 2024-02-01

37 papers 4,050 citations

411340 20 h-index 37 g-index

39 all docs 39 docs citations

39 times ranked 6674 citing authors

#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq $1\ 1\ 0.784314\ rgBT/Ov$	reglock 10	Tf,50,742 Te
2	Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature, 1998, 391, 815-818.	13.7	1,015
3	Biochemical, Structural, and Biological Evaluation of Tranylcypromine Derivatives as Inhibitors of Histone Demethylases LSD1 and LSD2. Journal of the American Chemical Society, 2010, 132, 6827-6833.	6.6	261
4	Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis. Cancer Cell, 2019, 35, 798-815.e5.	7.7	212
5	Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents. Scientific Reports, 2016, 6, 24460.	1.6	112
6	Astaxanthin Ameliorates Doxorubicin-Induced Cognitive Impairment (Chemobrain) in Experimental Rat Model: Impact on Oxidative, Inflammatory, and Apoptotic Machineries. Molecular Neurobiology, 2018, 55, 5727-5740.	1.9	110
7	Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO Journal, 2004, 23, 1144-1154.	3.5	109
8	Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries. Chemico-Biological Interactions, 2014, 217, 28-40.	1.7	75
9	Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent. Journal of Medicinal Chemistry, 2016, 59, 1501-1517.	2.9	70
10	Beclin 1 restrains tumorigenesis through Mcl-1 destabilization in an autophagy-independent reciprocal manner. Nature Communications, 2014, 5, 5637.	5.8	65
11	Chemotherapy and cognition: comprehensive review on doxorubicin-induced chemobrain. Cancer Chemotherapy and Pharmacology, 2019, 84, 1-14.	1.1	65
12	Dual modulation of MCL-1 and mTOR determines the response to sunitinib. Journal of Clinical Investigation, 2016, 127, 153-168.	3.9	49
13	Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. Blood, 2015, 126, 2392-2403.	0.6	48
14	Surmounting the resistance against EGFR inhibitors through the development of thieno [2,3-d] pyrimidine-based dual EGFR/HER2 inhibitors. European Journal of Medicinal Chemistry, 2018, 155, 316-336.	2.6	46
15	The tyrosine kinase inhibitor, sunitinib malate, induces cognitive impairment in vivo via dysregulating VEGFR signaling, apoptotic and autophagic machineries. Experimental Neurology, 2016, 283, 129-141.	2.0	39
16	Mechanistic approach of the inhibitory effect of chrysin on inflammatory and apoptotic events implicated in radiation-induced premature ovarian failure: Emphasis on TGF- $\hat{l}^2$ /MAPKs signaling pathway. Biomedicine and Pharmacotherapy, 2019, 109, 293-303.	2.5	36
17	Rational design, synthesis and molecular modeling studies of novel anti-oncological alkaloids against melanoma. Organic and Biomolecular Chemistry, 2015, 13, 6619-6633.	1.5	34
18	Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer. International Journal of Cancer, 2019, 145, 1991-2001.	2.3	32

#	Article	IF	CITATIONS
19	Serum sclerostin and irisin as predictive markers for atherosclerosis in Egyptian type II diabetic female patients: A case control study. PLoS ONE, 2018, 13, e0206761.	1.1	27
20	Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis. Medical Hypotheses, 2021, 146, 110365.	0.8	24
21	From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib. Frontiers in Pharmacology, 2017, 8, 718.	1.6	23
22	Modulation of Imatinib Cytotoxicity by Selenite in <scp>HCT</scp> 116 Colorectal Cancer Cells. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 37-46.	1.2	21
23	Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition. Haematologica, 2020, 105, 2105-2117.	1.7	20
24	Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: From bench to bedside. Cancer Treatment Reviews, 2015, 41, 754-760.	3.4	19
25	Comparative study of anti-VEGF Ranibizumab and Interleukin-6 receptor antagonist Tocilizumab in Adjuvant-induced Arthritis. Toxicology and Applied Pharmacology, 2018, 356, 65-75.	1.3	19
26	Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML. Oncogene, 2022, 41, 878-894.	2.6	17
27	A novel autophagy-independent, oncosuppressive function of BECN1: Degradation of MCL1. Autophagy, 2015, 11, 581-582.	4.3	16
28	Semantic and Geographical Analysis of COVID-19 Trials Reveals a Fragmented Clinical Research Landscape Likely to Impair Informativeness. Frontiers in Medicine, 2020, 7, 367.	1.2	8
29	Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia. Bioorganic and Medicinal Chemistry, 2022, 56, 116596.	1.4	8
30	Comparing apples with oranges: Studying LSD1 inhibitors in cellular assays. Pharmacological Research, 2019, 146, 104345.	3.1	7
31	Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside. European Journal of Cancer, 2019, 122, 22-41.	1.3	7
32	Endosomal trafficking and DNA damage checkpoint kinases dictate survival to replication stress by regulating amino acid uptake and protein synthesis. Developmental Cell, 2021, 56, 2607-2622.e6.	3.1	6
33	Indolin-2-one derivatives as selective Aurora B kinase inhibitors targeting breast cancer. Bioorganic Chemistry, 2021, 117, 105451.	2.0	6
34	Novel molecular mechanisms underlying the ameliorative effect of N-acetyl-L-cysteine against Ï'-radiation-induced premature ovarian failure in rats. Ecotoxicology and Environmental Safety, 2020, 206, 111190.	2.9	5
35	Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication. Leukemia, 2022, 36, 1306-1312.	3.3	3
36	Preclinical activity of fluvastatinâ€loaded selfâ€nanoemulsifying delivery system against breast cancer models: Emphasis on apoptosis. Journal of Cellular Biochemistry, 2022, 123, 947-963.	1.2	3

#	Article	IF	CITATIONS
37	Insights into the design of inhibitors of the EGFR family with anticancer activity overcoming resistance: A case of optimizing thieno[2,3-d]pyrimidine-based EGFR inhibitors. Journal of Molecular Structure, 2022, 1259, 132724.	1.8	3